31 results about "Melanopsin" patented technology

This invention provides conjugates of therapeutic or active agents with melanotransferrin or with other ligands of a melanotransferrin receptor, melanotransferrin receptor modulators, and related compositions and methods for modulating blood-brain barrier transport by, providing methods of screening and selecting such conjugates, ligands, and modulators in vitro and in vivo, and methods of use of such conjugates, modulators and ligands in diagnosis and the treatment of diseases, including particularly diseases of the central nervous system or lysosomal storage diseases.

The invention provides a three-channel lighting apparatus with the option to support the human circadian rhythm. By choosing especially the blue LED and green phosphor, the range of biological activity that can be changed is optimized. By adjustment of the LED spectra a bigger range in melanopsin effectiveness factor, at the same CCT range (from daylight like CCT down to dimmed halogen), can be obtained.

A light source and a method of generating a light using the light source is disclosed. The light source is configured to produce a plurality of distinct colors in generating the light, one of the distinct colors falling within a blue spectral light band. A light controller modulates the spectral light produced by the plurality of distinct colors. The modulation provides melanopsin contrast in order to increase melanopsin responsiveness of a subject exposed to the generated light and maintains the color temperature, color quality, and color constancy experienced by the subject in a lit viewing environment within an acceptable range.

A light-sensitive chimeric protein comprising domains from at least two members of the G-protein-coupled-receptor (GPCR) protein super family, which are fused to yield a light-sensitive GPCR chimera capable of coupling a light signal to the signaling cascade of the metabotropic glutamate receptor 6 (mGluR6) is provided for medical therapy and for the manufacture of medicaments for improving vision, in particular for treating loss of vision resulting from retinal photoreceptor degeneration. A first of the at least two GPCR family members contributes domains which mediate the light-sensitivity to the chimeric light-sensitive GPCR protein. This first member belongs to the family of light-sensitive GPCR proteins also called photopigments, and in some embodiments this light-sensitive GPCR protein is melanopsin, in particular human melanopsin. A second of the at least two GPCR family members is mGluR6, which contributes domains for coupling the light signal to the intracellular signalling cascade of mGluR6, which is a native component of the cell membrane of ON-bipolar cells in the inner retina.

A peptide formed from the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, according to the present invention, shows a melanogenesis increment activity and an adipogenesis inhibitory activity. A peptide of the present invention, by increasing phosphorylation of MITF, which is a transcription factor for increasing a tyrosinase expression, and CREB for increasing an MITF expression, consequently increases a tyrosinase expression and ultimately increases melanin synthesis. A peptide of the present invention, by reducing the amount of fat accumulated inside a cell and reducing expressions of perilipin and PPARγ, which contribute to adipogenic mechanism, ultimately inhibits adipogenesis. The present invention provides a composition for remedying or treating melanin hypopigmentation, the composition comprising the peptide, and provides pharmaceutical composition for treating or preventing obesity.

Tissue slices and whole organisms offer substantial challenges to fluorescence imaging. Autofluorescence and absorption via intrinsic chromophores, such as flavins, melanin, and hemoglobins, confound and degrade output from all fluorescent tags. An “optical window,” farther red than most autofluorescence sources and in a region of low hemoglobin and water absorbance, lies between 650 and 900 nm. This valley of relative optical clarity is an attractive target for fluorescence-based studies within tissues, intact organs, and living organisms. Novel fluorescent tags were developed herein, based upon a genetically targeted fluorogen activating protein and cognate fluorogenic dye that yields emission with a peak at 733 nm exclusively when complexed as a “fluoromodule”. This tool improves substantially over previously described far-red/NIR fluorescent proteins in terms of brightness, wavelength, and flexibility by leveraging the flexibility of synthetic chemistry to produce novel chromophores.

The invention belongs to the field of biological technology. The wild-type cinerea cinerea strain is used as the background strain to knock out the gene of a key enzyme cylindroxone dehydratase in the melanin synthesis pathway, and construct a gene deletion mutation of the cinerea cinerea capable of producing a large amount of cylindroxone The main steps of the strain Δbcscd1 are as follows: use fusion PCR technology to fuse the 5'-UTR and 3'-UTR of the target gene bcscd1 with the upstream and downstream coding regions of the hygromycin fragment Hph to obtain the upstream and downstream fusion fragments, and use PEG-mediated The protoplast transformation method was used to transform the fusion fragment into wild-type protoplasts for double-crossover homologous recombination, and the gene deletion mutant strain Δbcscd1 was obtained through screening and identification. The gene deletion mutant strain constructed by the method of the invention has high genetic stability and low toxicity. The present invention also proposes a method for specifically purifying cylindroporin through steps such as extraction, rotary steaming and column chromatography.

The invention relates to a peptide and a preparation method and application thereof. The peptide comprises a sequence as shown in SEQ ID No.1 or a sequence, where one or more amino acids are substituted, deleted, inserted and/added in the sequence as shown in SEQ ID No.1. The peptide displays activity of inhibiting melanoblast or melanogenesis or activity of whitening. The invention also providesa nucleotide sequence which encodes the peptide, a carrier containing the nucleotide sequence and a host comprising the vector. The peptide is similar to the amino acid sequence of MSH-alpha, and canbe prepared on a large scale by means of a biofermenting method, so that the peptide can be used for the whitening cosmetic industry.

An objective of this invention is to identify and provide a gene encoding medaka protein B. An additional objective of the present invention is to provide human and murine homologues of the gene. To achieve the above mentioned objectives, the inventors performed positional cloning on the B gene. The gene encoding medaka protein B was successfully isolated, and the present invention has come to completion. Accordingly, in accordance with the invention, there are provided a nucleic acid encoding medaka protein B and those encoding homologues thereof. According to another aspect of the invention, there are provided a nucleic acid listed in Seq. No. 1 that encodes medaka protein B and a nucleic acid listed in Seq. No. 3 that encodes mouse protein B/AIM-1. According to the invention, there is provided a method of suppressing melanin production characterized in that expression of the gene encoding protein B is suppressed.

An optical filter may reduce the frequency and/or severity of photophobic responses or for modulating circadian cycles by controlling light exposure to cells in the human eye in certain wavelengths, such as 480nm and 590nm, and a visual spectral response of the human eye. The optical filter may disrupt the isomerization of melanopsin in the human eye reducing the availability of the active isoform, whereas the attenuation of light weighted across the action potential spectrum of the active isoform attenuates the phototransduction cascade leading to photophobic responses. Embodiments of an optical filter are described. In one embodiment an optical filter may be configured to transmit less than a first amount of light in certain wavelengths, and to transmit more than a second amount of lightweighted across the visual spectral response. Methods of use and methods of manufacturing optical filters are also described.

A method of treating an eye disease comprising administering an adeno-associated virus (AAV) vector to a mammalian subject by subretinal injection, wherein the AAV vector comprises a nucleotide sequence encoding melanopsin operably linked to an expression control sequence to promote expression of melanopsin in cells of the eye of the subject.

Provided is a double-chain siRNA molecule targeting a microphthalmia-associated transcription factor MITF coding gene. A sense strand of the siRNA molecule has a sequence of SEQ ID NO: 3 and an anti-sense strand has a sequence of SEQ ID NO: 4, and the anti-sense strand specifically binds to mRNA of the MITF coding gene, to degrade the mRNA, thereby reducing the systhesis of melanin. Further provided is an application of the siRNA molecule in freckle whitening cosmetics or the preparation of medicines for treatment of diseases related to melanin gene.

Systems and methods are disclosed for creating high dynamic range (HDR) Neurally Primed Content (NPC) for stimulating a content viewer's melanopsin vision system (MVS), based on standard content, for viewing on a high dynamic range (HDR) display. The color and brightness information of a piece of standard content are analyzed. Based on the analysis, a color lookup table (CLUT) is created for use in converting the standard content color and brightness information to a higher bit depth representation of the color and brightness information. Using the CLUT and the standard content, a high dynamic range (HDR) logical representation of the content is creating having the higher bit depth. Finally, an NPC physical color representation of the higher bit depth HDR logical representation of the content is created for viewing on an HDR display.

The invention belongs to the technical field of optical radiation measurement, and particularly relates to a light environment test analyzer. The test analyzer comprises a light receiving module, a rhythm effect intensity analysis module, a spatial apparent brightness evaluation module, a directional positioning measurement module and a man-machine interaction module. Light radiation irradiates the light receiving module to obtain test light radiation, and the rhythm effect intensity analysis module calculates to obtain an equivalent visual melanin lux value index, and the spatial visual brightness evaluation module calculates to obtain a spatial visual brightness evaluation index; a test mode is selected through a control panel of the man-machine interaction module, a test state is started or quitted, test data is called or deleted, and a measurement result and the storage device can be transmitted through Bluetooth. Based on the photosensitive characteristic of human eye melanin protein, the rhythm effect intensity with direction or angle information can be directly measured, the accuracy of the measurement result is high, and the instrument is convenient and intuitive to operateand convenient to popularize.